BCTX Jun 2024 5.000 put
| Previous Close | 3.1000 |
| Open | 2.9500 |
| Bid | 3.3000 |
| Ask | 4.0000 |
| Strike | 5.00 |
| Expire Date | 2024-06-21 |
| Day's Range | 2.9500 - 3.1000 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 2 |
GlobeNewswireBriaCell Doubles Progression-Free-Survival (PFS) and Reports Clinical Benefit Data at ASCO 2024
83% intracranial objective response rate (iORR) with Bria-IMT™ in heavily pretreated advanced breast cancer patients with CNS metastasesMedian progression free survival (PFS) of 4.1 months in ADC resistant patients - double the PFS of patients in similar studies1,2,3Clinical benefit rate of 55% in evaluable patients includes HR+, HER2+ and TNBC disease - much higher than comparable studies1,2,3 PHILADELPHIA and VANCOUVER, British Columbia, May 24, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics C
Simply Wall St.This BriaCell Therapeutics Insider Increased Their Holding By 55% Last Year
Looking at BriaCell Therapeutics Corp.'s ( TSE:BCT ) insider transactions over the last year, we can see that insiders...
- GlobeNewswire
BriaCell Therapeutics Announces Closing of $5.0 Million Registered Direct Offering
PHILADELPHIA and VANCOUVER, British Columbia, May 17, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced it has closed its previously announced registered direct offering with healthcare-focused institutional investors and a certain existing investor and a director of the Company for the purchase and sale of 2,402,9
